Alla Paskovaty, PharmD

Seres Therapeutics
New York, New York, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• LB15 - SER-109, an Investigational Microbiome Therapeutic, Reduces Abundance of Antimicrobial Resistance Genes in Patients with Recurrent Clostridioides difficile Infection (rCDI) after Standard-of-Care Antibiotics

  Saturday, October 2, 2021
  1:15 PM - 3:00 PM EDT